PUBLISHER: The Business Research Company | PRODUCT CODE: 1350842
PUBLISHER: The Business Research Company | PRODUCT CODE: 1350842
“Chronic Kidney Disease Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on chronic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for chronic kidney disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The chronic kidney disease market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Major players in the chronic kidney disease market are: Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, and ProKidney Corp.
The global chronic kidney disease market is expected to grow from $61.51 billion in 2022 to $65.74 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The chronic kidney disease market is expected to reach $82.96billion in 2027 at a CAGR of 6%.
The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Chronic kidney disease is characterized by the inability of damaged kidneys to efficiently filter blood, resulting in excess fluid and blood waste in the body, potentially leading to health problems. It is commonly caused by diabetes, high blood pressure, and obesity. It requires careful, ongoing management and has the potential to proceed to end-stage renal failure requiring dialysis or transplant.
North America was the largest region in the chronic kidney disease market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic kidney disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa
The main diagnostic tests for chronic kidney disease are blood tests, urine tests, imaging tests, and a kidney biopsy. A blood test refers to the scientific examination of a blood sample that will be examined medically. The various types of treatments include drugs, dialysis, kidney transplants, ACE inhibitors, blood tests, and others. These drugs are administered through oral, intravenous, and subcutaneous routes of administration, and are used by various end-users, such as hospitals and clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.
The increasing prevalence of kidney disease is expected to propel the growth of the chronic kidney disease market going forward. Kidney diseases refer to a group of conditions that affect the function and structure of the kidneys. Medication for kidney disease is used to control blood pressure in patients and decrease protein loss to halt the progression of kidney impairment, manage symptoms, and avoid consequences. For instance, in July 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, around 15%, or 37 million people in the US, were affected by kidney disease. Furthermore, according to a report from the Australian Institute of Health and Welfare, an Australia-based Government agency, the prevalence of kidney replacement therapy in 2020 was 95.4 (per 100,000 population), up from 94 (per 100,000 population) in 2019. Therefore, the increasing prevalence of kidney disease is driving the growth of the chronic kidney disease market.
Product innovations are a key trend gaining popularity in the chronic kidney disease market. Companies operating in the chronic kidney disease market are developing innovative products to sustain their position in the market. For instance, in August 2022, Bayer, a Germany-based biotechnology and pharmaceutical company, launched the innovative medicine Kerendia (finerenone) to slow down the progression of chronic kidney disease in diabetes patients. It is a first-in-class non-steroidal, selective mineralocorticoid receptor antagonist and differs from existing treatments. It blocks mineralocorticoid receptor (MR) overactivation, contributing to CKD progression and cardiovascular damage.
In January 2023, AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. The acquisition will add CinCor's candidate medicine, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure control in treatment-resistant hypertension, to AstraZeneca's cardiorenal pipeline. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company that develops products to treat resistant and uncontrolled hypertension and chronic kidney disease.
The countries covered in the chronic kidney disease market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The chronic kidney disease market research report is one of a series of new reports from The Business Research Company that provides chronic kidney disease market statistics, including the chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.